Aethlon Medical, Inc.
AEMDHealthcareNASDAQMedical Devices · Last scanned Jul 22, 2026
Scan Results
Daily timeframeAethlon Medical, Inc., a medical therapeutic company, engages in developing novel immunotherapeutic devices in the United States. The $1.6M market capitalization puts AEMD squarely in micro-cap range for its industry. It develops Hemopurifier, a clinical-stage immunotherapeutic device intended to address unmet needs in oncology, life-threatening infectious diseases, organ transplantation, and other disease states.
Market Cap
$1.6M
Beta
1.41
P/E (TTM)
—
P/E (Fwd)
-1.22
EPS (TTM)
$-10.76
EPS (Fwd)
$-0.50
ROE
-142.9%
ROA
-66.6%
Cash
$5.0M
Total Debt
$514,816
Free CF
-$4.5M
52W Change
-95.5%
Annual Financials
Cash vs Debt
Where AEMD stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, AEMD finished 68.49% below its 150-day moving average ($2.19) and 77.08% below its 200-day moving average ($3.01). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is AEMD overbought or oversold?
At the July 15, 2026 close, AEMD's RSI(14) was 12.7, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $5.0M in cash and $515K in debt, AEMD maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$4.5M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -142.9%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $574K (2023) to $0 (2026), a 100% decline worth watching.
With cash comfortably exceeding debt, AEMD has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Aethlon Medical, Inc.'s trajectory.